Regenxbio Inc (NAS:RGNX)
$ 14.31 -0.04 (-0.28%) Market Cap: 704.85 Mil Enterprise Value: 455.37 Mil PE Ratio: 0 PB Ratio: 1.80 GF Score: 59/100

Regenxbio Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 02:10PM GMT
Release Date Price: $23.54 (-1.51%)
Swapnil Malekar
Piper Sandler Companies - Analyst

Good morning, everyone. My name is Swapnil Malekar. I am one of the biotech analysts here at Piper Sandler. It is with great pleasure that I want to introduce Ken Mills, who is the CEO of REGENXBIO, a very interesting gene therapy company working in different indications, with lead asset and several retinal and eye indications. So, Ken?

Ken Mills
REGENXBIO Inc. - President & CEO

Swapnil, thank you. Thanks to Piper for the invitation and for the continued support. Enjoying today to have the opportunity in person to present information about our company, REGENXBIO. There will be -- the lawyers tell me to be careful about forward-looking statements. But to the extent that I slip, we've got SEC documents that will back us up.

The mission of REGENXBIO is seeking to improve lives through the curative potential of gene therapy. We are an in vivo gene therapy company using AAV technology. The history of the company is that in the mid- to late-2000s, there was buy-ins that were done that we thought were

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot